


Substitute for form 144B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		(use as many sheets as necessary)		Application Number	10/016,743
				Filing Date	November 2, 2001
				First Named Inventor	Sabb et al.
				Group Art Unit	1624
				Examiner Name	B. Coleman
Sheet	1	of	2	Attorney Docket Number	AM100317

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (If known)	Kind Code (If known)			
BC	1.	2002/0107242	A1	American Home Products Corp.	08-08-2002	
BC	2.	5,834,454	A	Sumitomo Pharmaceuticals Co.	11-10-1998	
BC	3.	2002/0173503	A1	Bristol-Myers Squibb Pharma	11-21-2002	
BC	4.	3,714,149		The Upjohn Company	01-30-1973	
BC	5.	3,417,101		American Home Products Corp.	12-17-1968	
BC	6.	3,329,676		S.C. Bell et al.	07-04-1967	
BC	7.	5,045,545		Glaxo Group Ltd.	09-03-1991	
BC	8.	4,997,831		Glaxo Group Ltd.	03-05-1991	
BC	9.	3,466,274		Rene R. DeRidder	09-09-1969	
BC	10.	3,335,134		Sandoz Inc.	08-08-1967	
BC	11.	3,296,252		Sandoz Inc.	01-03-1967	
BC	12.	3,235,564		G.D. Searle & Co.	02-15-1966	
BC	13.	2003/0050300	A1	William W. McWhorter Jr.	03-13-2003	

RECEIVED

DEC 24 2003

TECH CENTER 1600/2900


FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (If known)				
BC	14.	WO	96/29316	A1	Wikstrom	09-26-1996		<input type="checkbox"/>
BC	15.	WO	00/35922	A1	American Home Products Corp.	06-22-2000		
BC	16.	WO	02/08186	A2	Merck Frosst Canada & Co.	01-31-2002		
BC	17.	WO	02/42304	A2	Wyeth	05-30-2002		
BC	18.	WO	02/059124	A2	Bristol-Myers Squibb Co.	08-01-2002		
** BC	19.	JP	10-237073 (U.S. Equiv. 5,834,454)		Sumitomo Pharmaceuticals	09-08-1998		
BC	20.	WO	00/77002	A1	DuPont Pharmaceuticals Co.	12-21-2000		
BC	21.	WO	90/15058	A1	The Upjohn Company	12-13-1990		
BC	22.	WO	02/059129	A2	Bristol-Myers Squibb Co.	08-01-2002		
BC	23.	WO	99/67219	A1	Elan Pharmaceuticals, Inc.	12-29-1999		
BC	24.	WO	99/66934	A1	Elan Pharmaceuticals, Inc.	12-29-1999		
** BC	25.	SU	930902		S. Ordzhonikidze	11-19-1982		
BC	26.	WO	00/64899	A1	Pharmacia & Upjohn Co.	11-02-2000		
BC	27.	WO	97/31000	A1	Chiroscience Ltd.	08-28-1997		
BC	28.	EP	0357417	A1	Glaxo Group Ltd.	03-07-1990		
BC	29.	EP	0344015	A2	Glaxo Group Ltd.	11-29-1989		
BC	30.	WO	01/12603	A1	Vernalis Research Ltd.	02-22-2001		
BC	31.	WO	02/36596	A2	Wyeth	05-10-2002		
BC	32.	WO	02/42304	A2	Wyeth	05-30-2002		
BC	33.	WO	97/30999	A1	Chiroscience Ltd.	08-28-1997		

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		
BC	34.	P.J. COWEN et al., Nature 376, 557 (August 1995).		<input type="checkbox"/>
BC	35.	A.J. ROBICHAUD et al., Annual Reports in Medicinal Chemistry, 35, 11-20 (2000).		
BC	36.	D. HOYER et al., Pharmacology & Experimental Therapeutics 46(2), 157-203 (1994).		

Examiner Signature	Brenda Coleman	Date Considered	Feb. 22, 2004
--------------------	----------------	-----------------	---------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

** structures only

Substitute for form 144B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/016,743
(use as many sheets as needed)				Filing Date	November 2, 2001
				First Named Inventor	Sabb et al.
				Group Art Unit	1624
				Examiner Name	B. Coleman
Sheet	2	of	2	Attorney Docket Number	AM100317

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
BC	37.	L. TECOTT et al., Nature, 374, 542-546 (April 1995).	
BC	38.	D.H. KIM, J. Heterocycl. Chem., 12, 1323-1324 (December 1975).	
BC	39.	M.J. BISHOP et al., Expert Opin. Ther. Patents, 13(11), 1691-1705 (2003).	
BC	40.	SHUNJI NARUTO et al., Tetrahedron Letters, 39, 3399-3402 (1975).	
BC	41.	A.N. GRINEV et al., Chem. Heterocycl. Compd., 19(9), 959-961 (1983).	<input type="checkbox"/>
BC	42.	A.N. GRINEV et al., Chem. Heterocycl. Compd., 19(12), 1312-1315 (1983).	
BC	43.	E.V. LAMANOVA et al., Pharm. Chem., J., 23(2), 113-115 (1989).	
BC	44.	D.H. KIM et al., Journal of Medicinal Chemistry, 20(2), 209-212 (1977).	
BC	45.	L. TOSCANO et al., J. Heterocyclic Chem., 13, 475-480 (1976).	
BC	46.	A. KATRITZKY et al., Synthesis, 10, 1487-1490 (1998).	
BC	47.	F. GATTA et al., Edizione Scientifica, 30(8), 631-641 (1975).	
BC	48.	W. LOPES et al., Journal of Brazilian Chemical Society, 4(1), 34-39 (1993).	

RECEIVED

DEC 24 2003

TECH CENTER 1600/2900

Examiner Signature	Brenda Coleman	Date Considered	Feb. 22, 2004
-----------------------	----------------	--------------------	---------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.